September 19, 2016 08:22 AM EDT
R&D

Lead vac­cine from Vi­cal and Astel­las flops in a Phase II her­pes study

Arsalan Arif

Founder

San Diego-based Vi­cal $VI­CL says that its lead vac­cine ASP0113 flopped in a Phase II study de­signed to thwart her­pes in kid­ney trans­plant pa­tients. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The in­side sto­ry of how Sali­o­Gen, a start­up try­ing to wran­gle ‘jump­ing genes’ to make med­i­cines, fell apart

Miss­ing REMS de­lays Cy­to­ki­net­ic­s' heart drug PDU­FA, stock drops

For­mer Tome CEO joins Flag­ship start­up; NGM Bio chief steps down as re­struc­tur­ing takes ef­fect

In­vestors un­veil plans for $1.3B can­cer hub in Lon­don sub­urbs

US drug­mak­ers in­creas­ing­ly look abroad for clin­i­cal tri­als as con­fi­dence in FDA wa­vers

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times